Ignite Creation Date:
2025-12-25 @ 4:32 AM
Ignite Modification Date:
2025-12-26 @ 3:34 AM
Study NCT ID:
NCT07139418
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-08-24
First Post:
2025-08-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Impact of Gastric Mesentery With Lymph Node Metastasis on Prognosis in Gastric Cancer Patients
Sponsor:
Jichao Qin
Organization:
Study Overview
Official Title:
Exploring the Predictive Value of Lymph Node Examination From Different Gastric Mesenteric Regions for Prognosis After D2 Lymphadenectomy Plus Complete Mesogastric Excision in Gastric Cancer Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to validate the predictive value of lymph node-metastasis gastric mesenteric regions and their quantitative involvement for gastric cancer prognosis by systematically examining lymph nodes from distinct mesenteric compartments in post-D2+CME radical gastrectomy specimens.
Detailed Description:
Prior to 2010, the gastric cancer nodal staging systems primarily consisted of two approaches: the UICC/AJCC classification (by the International Union Against Cancer/American Joint Committee on Cancer), which was based principally on the number of metastatic lymph nodes; and the JGCA system (by the Japanese Gastric Cancer Association), which focused on the anatomical location of nodal metastases. However, a landmark unification occurred in the 14th edition of the Japanese Classification of Gastric Carcinoma (2010), where the anatomically-based nodal staging was abolished in favor of a metastasis-counting method. This harmonization with the UICC/AJCC system established a globally authoritative standard for evaluating therapeutic outcomes in gastric cancer, representing a milestone advancement in clinical research.
The current staging standard for gastric cancer follows the 8th edition TNM classification system (effective 2017) jointly established by the UICC (International Union Against Cancer) and AJCC (American Joint Committee on Cancer), which primarily evaluates tumor invasion depth (T), lymph node metastasis extent (N), and distant metastasis status (M). By integrating these three parameters, gastric cancer is classified into stages 0 through IV to guide treatment decisions and prognostic assessment. The gastric mesentery contains vascular, adipose, neural, and lymphoid tissues and can be anatomically divided into the left gastric mesentery, right gastric mesentery, left gastroepiploic mesentery, right gastroepiploic mesentery, posterior gastric mesentery, and short gastric mesentery. Although the anatomical location of metastatic lymph nodes is no longer included in the current gastric cancer staging system, our institutional research has demonstrated that among patients with the same N-stage, those with a greater number of lymph node-positive mesenteric regions exhibit worse prognosis, indicating that the anatomical distribution of nodal metastases remains clinically significant for gastric cancer outcomes. This study proposes to separately submit post-gastrectomy specimens with lymph nodes grouped by distinct mesenteric regions, with intraoperative demarcation of mesenteric boundaries during D2+CME surgery to achieve precise postoperative mesenteric sorting. Compared to the lymph node grouping method specified in the 15th edition of the Japanese Gastric Cancer Association's "Japanese Classification of Gastric Carcinoma" (2017), submitting lymph nodes according to mesenteric regions offers greater practicality. By examining gastric lymph nodes from separate mesenteric compartments, we aim to further investigate how the specific locations of lymph node-positive mesenteric regions and the total number of involved mesenteric areas impact gastric cancer patient prognosis, thereby enabling more accurate prediction of clinical outcomes.
The current staging standard for gastric cancer follows the 8th edition TNM classification system (effective 2017) jointly established by the UICC (International Union Against Cancer) and AJCC (American Joint Committee on Cancer), which primarily evaluates tumor invasion depth (T), lymph node metastasis extent (N), and distant metastasis status (M). By integrating these three parameters, gastric cancer is classified into stages 0 through IV to guide treatment decisions and prognostic assessment. The gastric mesentery contains vascular, adipose, neural, and lymphoid tissues and can be anatomically divided into the left gastric mesentery, right gastric mesentery, left gastroepiploic mesentery, right gastroepiploic mesentery, posterior gastric mesentery, and short gastric mesentery. Although the anatomical location of metastatic lymph nodes is no longer included in the current gastric cancer staging system, our institutional research has demonstrated that among patients with the same N-stage, those with a greater number of lymph node-positive mesenteric regions exhibit worse prognosis, indicating that the anatomical distribution of nodal metastases remains clinically significant for gastric cancer outcomes. This study proposes to separately submit post-gastrectomy specimens with lymph nodes grouped by distinct mesenteric regions, with intraoperative demarcation of mesenteric boundaries during D2+CME surgery to achieve precise postoperative mesenteric sorting. Compared to the lymph node grouping method specified in the 15th edition of the Japanese Gastric Cancer Association's "Japanese Classification of Gastric Carcinoma" (2017), submitting lymph nodes according to mesenteric regions offers greater practicality. By examining gastric lymph nodes from separate mesenteric compartments, we aim to further investigate how the specific locations of lymph node-positive mesenteric regions and the total number of involved mesenteric areas impact gastric cancer patient prognosis, thereby enabling more accurate prediction of clinical outcomes.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: